Skip to main content

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708456/Champions-Oncology-to-Announce-Fourth-Quarter-Financial-Results-on-Thursday-July-21-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.45
-1.08 (-0.46%)
AAPL  272.94
-0.14 (-0.05%)
AMD  215.30
-0.04 (-0.02%)
BAC  55.16
-0.12 (-0.23%)
GOOG  314.49
-0.06 (-0.02%)
META  662.03
-3.92 (-0.59%)
MSFT  485.43
-2.05 (-0.42%)
NVDA  187.68
+0.14 (0.08%)
ORCL  196.16
-1.05 (-0.53%)
TSLA  452.45
-1.98 (-0.44%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.